![An artistic illustration of a purple-magenta flower with a bright center that extends out into the petals in a fractal pattern style.](https://dianthustx.com/wp-content/uploads/2023/07/approach-and-pipeline-img.png)
![An artistic illustration of a purple-magenta flower with a bright center that extends out into the petals in a fractal pattern style.](https://dianthustx.com/wp-content/themes/genesis-child/dist/images/approach-and-pipeline-desktop-img.png)
approach & pipeline
DEFINED TARGETS.
BOUNDLESS IMPACT.
Dianthus Therapeutics is harnessing the power of selectivity to advance next-generation complement therapies to treat severe autoimmune diseases.
![An artistic illustration of the immunoglobulin M (IgM) molecule shown in light purple, with a blue substructure attached to it.](https://dianthustx.com/wp-content/uploads/2023/07/unmet-need-img.png)
OUR INNOVATION
Our lead antibody, DNTH103, is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections.
Addressing both the disease and treatment burdens that disrupt the lives of patients.
![An artistic illustration of an antibody in hues of blue and teal.](https://dianthustx.com/wp-content/uploads/2023/07/innovation-img.png)
OUR FOCUS
DNTH103 is an investigational, long-acting monoclonal antibody engineered to potently and selectively inhibit the active form of C1s, a clinically validated target in the classical complement pathway.
As the classical pathway plays a significant role in disease pathology across a range of neuromuscular disorders, DNTH103 holds the potential to be a pipeline in a product – beginning with generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.
Engineered with YTE half-life extension technology, DNTH103 is intended to be the first subcutaneous complement therapy that can be self-administered as infrequently as once every two weeks for patients with severe, classical pathway-driven autoimmune disorders.
So patients can live healthier lives to their fullest potential.
![Scientific illustration of how Dianthus engineers its antibodies to target only the active form of complement proteins.](https://dianthustx.com/wp-content/uploads/2023/06/cells.jpg)
![Scientific illustration of how Dianthus engineers its antibodies to target only the active form of complement proteins.](https://dianthustx.com/wp-content/uploads/2023/07/cells-mobile-1-scaled.jpg)
![Curved Shapes](https://dianthustx.com/wp-content/themes/genesis-child/dist/images/curved-top.png)
BUILDING A NEUROMUSCULAR FRANCHISE WITH DNTH103
Positive top-line Phase 1 data for DNTH103 from 60 healthy volunteers across eight single and multiple-ascending dose cohorts validate DNTH103’s potent classical pathway inhibition with an approximate 60-day extended half-life and a potentially differentiated safety profile. Dianthus is building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis in 1Q’24, regulatory clearance for Multifocal Motor Neuropathy in 2Q’24, and planned initiation of a Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy in 2H’24.
PIPELINE
DNTH103 – subcutaneous active C1s antibody
Approximately 60,000 people in the United States live with gMG, a chronic autoimmune disorder that causes progressive muscle weakness. About 85% of people with gMG have AChR autoantibody-driven disease, a driven by classical complement pathway activation.
Approximately 5,000 to 10,000 people in the United States live with MMN, a disease in which the immune system attacks peripheral nerve axons and myelin sheaths and classical complement pathway activation can facilitate progressive nerve damage. Up to 80% of patients are not adequately managed by current standard of care and there are no approved targeted biologic therapies for MMN.
Approximately 15,000 people in the United States live with CIDP, a neuromuscular condition driven by classical pathway activation that follows a relapsing-remitting or a progressive clinical course with the potential to result in substantial disability, loss of motor and sensory function. There are no approved targeted biologic therapies for CIDP.
Ongoing Discovery
![Curved Shapes](https://dianthustx.com/wp-content/themes/genesis-child/dist/images/curved-bottom.png)